Placebo groups showed minimal HbA1c changes, ranging from about -0.2% to -0.4%.

Injectable amycretin produced meaningful HbA1c reductions in adults with uncontrolled diabetes on metformin, cutting HbA1c by up to 1.8 percentage points from a baseline around 7.8%, with a large share reaching target levels (about 89% below 7% and roughly 76% at or below 6.5%).

Cohorts receiving subcutaneous injections and weekly oral dosing both achieved substantial portions reaching target HbA1c; in the Week 36 assessment, 89.1% of the injection group were under 7% and 76.2% were at or below 6.5%, while in the daily oral group 77.6% were under 7% and 62.6% were at or below 6.5%.

Oral amycretin lowered HbA1c by as much as 1.5 percentage points from a baseline of 8.0%, with 78% achieving HbA1c below 7% and 63% at or below 6.5%.

Novo Nordisk’s chief scientific officer highlighted this as the first evaluation of amycretin in Type 2 diabetes and noted potential meaningful implications for patients and their comorbidities.

The market responded positively to the data release, with Novo’s stock rising more than 4% to around 300 Danish kroner.

Novo cautioned that amycretin could match the safety, tolerability, and efficacy of CagriSema, presenting a single-molecule alternative within the same receptor-target class.

The Phase 2 study enrolled 448 adults with inadequately controlled Type 2 diabetes on metformin (with or without SGLT2 inhibitors), evaluating six injectable and three oral doses over up to 36 weeks.

Safety was dominated by mild to moderate gastrointestinal events, consistent with expectations for incretin and amylin-based therapies.

The overall safety profile aligned with other incretin and amylin-based therapies, featuring mostly mild-to-moderate GI side effects.

Novo Nordisk plans to push amycretin into a full Phase 3 program for adults with type 2 diabetes in 2026 to establish a lead in metabolic medicine, building on positive Phase 2 results that position the drug as a novel dual-acting therapy targeting GLP-1 and amylin receptors.

Leadership suggests the data support amycretin’s potential best-in-class profile in this space.

Phase 2 findings show dose-dependent HbA1c reductions, with subcutaneous dosing achieving up to a 1.8 percentage point drop and oral dosing up to 1.5 points versus placebo by Week 36.

Weight loss accompanied HbA1c improvements, with injectable amycretin achieving up to 14.5% weight reduction and oral dosing up to 10.1%, compared with minimal changes in placebo.

Weight loss benefits persisted through Week 36 for higher-dose groups, reinforcing the metabolic advantages observed with amycretin.